ライフサイエンスコーパス: Streptococcus pyogenes

1 ting infection with the riboflavin auxotroph Streptococcus pyogenes.

2 can enter human cells and kill intracellular Streptococcus pyogenes.

3 yte activation in response to infection with Streptococcus pyogenes.

4 s II-bound peptide from the mucosal pathogen Streptococcus pyogenes.

5 ions of adhesion proteins from the bacterium Streptococcus pyogenes.

6 urface of invasive M3-type strain MGAS315 of Streptococcus pyogenes.

7 treptolysin O (SLO), a virulence factor from Streptococcus pyogenes.

8 e 8 charged residues in YtgP, a homolog from Streptococcus pyogenes.

9 lycoside-hydrolase secreted by the bacterium Streptococcus pyogenes.

10 plays an important role in the virulence of Streptococcus pyogenes.

11 cribes such a situation after infection with Streptococcus pyogenes.

12 occus pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes.

13 using two rapid antigen detection assays for Streptococcus pyogenes.

14 ins are critical for the in vivo survival of Streptococcus pyogenes.

15 , including the clinically relevant pathogen Streptococcus pyogenes.

16 d to effectively identify DNA signatures for Streptococcus pyogenes.

17 phil peptide (HNP-1) with the human pathogen Streptococcus pyogenes.

18 AgI/II-family proteins are also expressed by Streptococcus pyogenes.

19 gous to the myosin cross-reactive antigen of Streptococcus pyogenes.

20 share homology with the mitogenic toxins of Streptococcus pyogenes.

21 Cas9 enzymes from Staphylococcus aureus and Streptococcus pyogenes.

22 toxins secreted by Staphylococcus aureus and Streptococcus pyogenes.

23 with PJI, namely, Staphylococcus aureus and Streptococcus pyogenes.

24 s aureus (10 [43.5%] vs 4 [12.9%]; P = .02), Streptococcus pyogenes (2 [8.7%] vs 19 [61.3%]; P < .001

25 9 are derived from Staphylococcus aureus and Streptococcus pyogenes(5,7).

26 mutagenesis approach, we have identified in Streptococcus pyogenes a gene that exhibits a receptor-l

27 r, pharyngitis resulting from infection with Streptococcus pyogenes (a group A Streptococcus [GAS]) c

28 In Streptococcus pyogenes, a common and potentially deadly

29 Streptococcus pyogenes, a human-restricted pathogen, acc

30 Streptococcus pyogenes, a multiple-auxotrophic human pat

31 Streptococcus pyogenes activates IFN-I production in inn

32 Here, we report that Streptococcus pyogenes also hijack lymphatic vessels to

33 The Gram-positive bacterium Streptococcus pyogenes (also called group A Streptococcu

34 Streptococcus pyogenes , also known as group A streptoco

35 ing a positive result for samples containing Streptococcus pyogenes and a negative result for those w

36 ride (RhaPS) that is essential for growth of Streptococcus pyogenes and contributes to its ability to

37 Cysteine protease SpeB is secreted from Streptococcus pyogenes and has been studied as a potenti

38 tudy, we created an RNase III null mutant of Streptococcus pyogenes and its RNA sequencing (RNA-Seq)

39 The type II CRISPR/Cas system from Streptococcus pyogenes and its simplified derivative, th

40 ce against lethal soft tissue infection with Streptococcus pyogenes and prevented bacterial dissemina

41 al effects against Staphylococcus aureus and Streptococcus pyogenes and protected against staphylococ

42 ive clinical diagnose include Staphylococci, Streptococcus pyogenes and Pseudomonas aeruginosa in ble

43 has never, or rarely, been reported for the Streptococcus pyogenes and S. bovis groups of species, e

44 Both Streptococcus pyogenes and Streptococcus pneumoniae are

45 mber of TCSs compared to the closely related Streptococcus pyogenes and Streptococcus pneumoniae, and

46 which includes common human pathogens, e.g., Streptococcus pyogenes and Streptococcus pneumoniae.

47 Only two CRISPR-Cas systems (from Streptococcus pyogenes and Streptococcus thermophilus),

48 Here, we combine the CRISPR system from Streptococcus pyogenes and synthetic antisense RNAs (asR

49 ular elements of patients with GP respond to Streptococcus pyogenes and whether this initial immune r

50 Neisseria gonorrhoeae, Salmonella enterica, Streptococcus pyogenes and Xenorhabdus nematophila.

51 utagenesis of EndoS (an endoglycosidase from Streptococcus pyogenes ) and were found to be capable of

52 oth gram-positive (Staphylococcus aureus and Streptococcus pyogenes) and gram-negative bacteria (Pseu

53 aphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, and Candida albicans.

54 us influenzae (NTHi), Moraxella catarrhalis, Streptococcus pyogenes, and culture-negative OM.

55 ease onset in children and associations with Streptococcus Pyogenes, and influenza A H1N1-infection a

56 map between the significant human pathogen, Streptococcus pyogenes, and proteins from human saliva a

57 tein 9 (Cas9) from Staphylococcus aureus and Streptococcus pyogenes, and recombinant Cas9 and develop

58 in 8 patients, and Streptococcus agalactiae, Streptococcus pyogenes, and Streptococcus salivarius in

59 Streptococcus pyogenes, and to a lesser extent, Staphylo

60 eus, methicillin-resistant S. aureus (MRSA), Streptococcus pyogenes, and vancomycin-resistant Enteroc

61 Herein, we report the development of the Streptococcus pyogenes anti-CRISPR/Cas9 protein, AcrIIA4

62 Streptococcus pyogenes AP1, a strain of the highly virul

63 li of the nasty gram-positive human pathogen Streptococcus pyogenes are assembled as single, micromet

64 The heme-binding proteins Shp and HtsA of Streptococcus pyogenes are part of the heme acquisition

65 coccus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, are most commonly isolated.

66 organisms, such as Staphylococcus aureus and Streptococcus pyogenes, are the dominant organisms isola

67 HIV-1 Gag-p24 on the tip of the T3 pilus of Streptococcus pyogenes as a fusion to the Cpa protein (L

68 inhibits growth of the pathogenic bacterium Streptococcus pyogenes as effectively as melittin create

69 The BC-GP detected a case of Streptococcus pyogenes bacteremia but failed to detect 2

70 (FUD), a polypeptide based on F1 adhesin of Streptococcus pyogenes, binds by anti-parallel beta-stra

71 ustom DNA-binding modules, the nuclease-dead Streptococcus pyogenes Cas9 (dCas9) protein, which recog

72 The targeting scope of Streptococcus pyogenes Cas9 (SpCas9) and its engineered

73 Although the widely used Streptococcus pyogenes Cas9 (SpCas9) and its engineered

74 e-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, poss

75 Here we show that the commonly used Streptococcus pyogenes Cas9 (SpCas9) can be modified to

76 The success of Streptococcus pyogenes Cas9 (SpCas9) has led to the disc

77 Here we detect antibodies to Streptococcus pyogenes Cas9 (SpCas9) in at least 5% of 1

78 The Streptococcus pyogenes Cas9 (SpCas9) nuclease can be eff

79 ontains a mutation in TCAP, treated with the Streptococcus pyogenes Cas9 (SpCas9) nuclease revealed t

80 first synthetic small-molecule inhibitors of Streptococcus pyogenes Cas9 (SpCas9) that weigh <500 Da

81 e this constraint, we engineered variants of Streptococcus pyogenes Cas9 (SpCas9) to eliminate the NG

82 udy by Walton et al. structurally engineered Streptococcus pyogenes Cas9 (SpCas9) to near-PAMless SpR

83 Streptococcus pyogenes Cas9 (SpCas9), a CRISPR-associate

84 because commonly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to

85 SaCas9), which is significantly smaller than Streptococcus pyogenes Cas9 (SpCas9), to facilitate effi

86 ss and efficiency as previously reported for Streptococcus pyogenes Cas9 (SpCas9).

87 lls comparable with those of the widely used Streptococcus pyogenes Cas9 (SpCas9).

88 in engineering to improve the specificity of Streptococcus pyogenes Cas9 (SpCas9).

89 fies single guide RNAs (sgRNAs) for use with Streptococcus pyogenes Cas9 (SpCas9).

90 NA cleavage beyond the 44 degrees C limit of Streptococcus pyogenes Cas9 (SpyCas9) and the 70 degrees

91 uman oral and fecal metagenomes that inhibit Streptococcus pyogenes Cas9 (SpyCas9) in Escherichia col

92 he most commonly used genome editing protein Streptococcus pyogenes Cas9 (SpyCas9), we used both self

93 o 70 degrees C, compared to 45 degrees C for Streptococcus pyogenes Cas9 (SpyCas9), which expands the

94 cus iniae Cas9 (SinCas9) and weakly inhibits Streptococcus pyogenes Cas9 (SpyCas9).

95 icity, selectivity, and reaction kinetics of Streptococcus pyogenes Cas9 activity, we challenged libr

96 Structures of Streptococcus pyogenes Cas9 alone or bound to single-gui

97 ng activity that are also among the smallest Streptococcus pyogenes Cas9 base editors described to da

98 Streptococcus pyogenes Cas9 cleavage of the viral genome

99 At low forces, the Streptococcus pyogenes Cas9 complex binds and cleaves DN

100 fications to the sugar-phosphate backbone of Streptococcus pyogenes Cas9 CRISPR RNA (crRNA) to probe

101 Here we show that the Streptococcus pyogenes Cas9 DNA endonuclease and single

102 DNA vectors expressing maize codon-optimized Streptococcus pyogenes Cas9 endonuclease and single guid

103 Here, we report the crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and it

104 g guide RNA (stgRNA) that repeatedly directs Streptococcus pyogenes Cas9 nuclease activity toward the

105 also compared the cleavage efficiency of the Streptococcus pyogenes Cas9 protein based on expression

106 cular structures of the catalytically active Streptococcus pyogenes Cas9 R-loop that show the displac

107 hese inhibitors also blocked the widely used Streptococcus pyogenes Cas9 when assayed in Escherichia

108 protein containing a catalytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and a

109 Applied to Streptococcus pyogenes Cas9, a Hamiltonian metric obtain

110 egulatory sequences to conditionally express Streptococcus pyogenes Cas9, and V. carteri U6 RNA gene

111 ing method using only the well-characterized Streptococcus pyogenes Cas9, by incorporating MS2 or PP7

112 However, in M. tuberculosis, the existing Streptococcus pyogenes Cas9-based CRISPRi system is of l

113 Streptococcus pyogenes Cas9-guide RNA (gRNA) was success

114 ence required for target site recognition by Streptococcus pyogenes Cas9.

115 ons, with most studies to date utilizing the Streptococcus pyogenes Cas9.

116 n of the protospacer-adjacent motif (PAM) of Streptococcus pyogenes Cas9.

117 For the Gram-positive pathogen Streptococcus pyogenes, catabolism of the amino acid arg

118 Streptococcus pyogenes causes 700 million human infectio

119 d expression and activity of SLO, DNase, and Streptococcus pyogenes cell envelope protease in vitro.

120 In the Streptococcus pyogenes collagen-like protein Scl2, a V d

121 etween sequence, stability, and folding, the Streptococcus pyogenes collagenous domain CL (Gly-Xaa-Ya

122 The CRISPRi system is derived from the Streptococcus pyogenes CRISPR (clustered regularly inter

123 The Cas9 protein from the Streptococcus pyogenes CRISPR-Cas acquired immune system

124 Using the Streptococcus pyogenes CRISPR-Cas adaptation machinery,

125 Type-II CRISPR-Cas systems, such as the Streptococcus pyogenes CRISPR-Cas9 system, can be adapte

126 e of the Aries GAS assay compared to that of Streptococcus pyogenes culture.

127 The Mga regulator of Streptococcus pyogenes directly activates the transcript

128 Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majo

129 reveal that a bacterial endoglycosidase from Streptococcus pyogenes , EndoS, is complementary to othe

130 ant bacterial pathogens in humans, including Streptococcus pyogenes, express surface proteins that bi

131 -residue functional upstream domain (FUD) of Streptococcus pyogenes F1 adhesin interacts with fibrone

132 Streptococcus pyogenes fibronectin-binding protein FbaB

133 to the surface of the human pathogen group A Streptococcus pyogenes (GAS) and subsequent hPg activati

134 Dimeric M-proteins (M-Prt) in group A Streptococcus pyogenes (GAS) are surface-expressed virul

135 Staphylococcus aureus and group A Streptococcus pyogenes (GAS) express superantigen (SAg)

136 A emm53 subclass of Group A Streptococcus pyogenes (GAS) interacts tightly with huma

137 Infection by Group A Streptococcus pyogenes (GAS) is a leading cause of sever

138 Group A Streptococcus pyogenes (GAS) is a leading human pathogen

139 Group A Streptococcus pyogenes (GAS) strain AP53 is a primary is

140 A skin-tropic invasive group A Streptococcus pyogenes (GAS) strain, AP53, contains a na

141 -mediated opsonophagocytosis enables group A Streptococcus pyogenes (GAS) to establish infection.

142 rt a population genomic study of the group A Streptococcus pyogenes (GAS), a human pathogen with high

143 treptococcus pyogenes (gram-positive group A Streptococcus pyogenes [GAS]) recruit host single-chain

144 The normalized fluorescence intensity of the Streptococcus pyogenes gave a signal that is up to 16.4

145 Virulent strains of Streptococcus pyogenes (gram-positive group A Streptococ

146 Infections caused by Streptococcus pyogenes (group A Streptococcus [GAS]) are

147 tics is a global concern in the treatment of Streptococcus pyogenes (group A Streptococcus [GAS]) inf

148 Rgg2 and Rgg3 (Rgg2/3) regulatory circuit of Streptococcus pyogenes (group A streptococcus [GAS]) is

149 Streptococcus pyogenes (group A Streptococcus [GAS]) is

150 Streptococcus pyogenes (group A streptococcus [GAS]) is

151 Streptococcus pyogenes (group A Streptococcus [GAS]) is

152 The important human pathogen Streptococcus pyogenes (group A Streptococcus [GAS]) pro

153 Streptococcus pyogenes (group A streptococcus [GAS]) res

154 Streptococcus pyogenes (group A Streptococcus [GAS]), a

155 e role of zinc efflux in the pathogenesis of Streptococcus pyogenes (group A Streptococcus [GAS]), a

156 d an RNase Y ortholog has been identified in Streptococcus pyogenes (group A streptococcus [GAS]).

157 a, including one (stk) in the human pathogen Streptococcus pyogenes (group A streptococcus [GAS]).

158 t to which glucose alters gene expression in Streptococcus pyogenes (group A streptococcus) and the c

159 All sequenced genomes of Streptococcus pyogenes (Group A Streptococcus, GAS) enco

160 the Gram-positive human-restricted pathogen Streptococcus pyogenes (Group A Streptococcus, GAS) has

161 The human-restricted pathogen Streptococcus pyogenes (Group A Streptococcus, GAS) is r

162 ity of North-East Asian serotype M12 (emm12) Streptococcus pyogenes (group A Streptococcus, GAS) to c

163 As a strict human pathogen, Streptococcus pyogenes (group A Streptococcus, or GAS) c

164 Streptococcus pyogenes (Group A Streptococcus; GAS) is a

165 Streptococcus pyogenes (Group A streptococcus; GAS) is a

166 of many human pathogenic bacteria, including Streptococcus pyogenes (Group A Streptococcus; GAS), Str

167 Streptococcus pyogenes [group A Streptococcus; (GAS)] is

168 rammed genome editing using CRISPR/Cas9 from Streptococcus pyogenes has enabled rapid and accessible

169 , formed autocatalytically, in the pili from Streptococcus pyogenes has highlighted the role that suc

170 mbinant immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) followed by chemical reduc

171 The IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves

172 bacterial protease, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), cleaves the hinge region

173 A bacterial enzyme, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), was shown to specifically

174 use of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), which is capable of diges

175 A reactivity against IgG-degrading enzyme of Streptococcus pyogenes (IdeS)- or pepsin-generated F(ab'

176 ors of the bacterial IgG degrading enzyme of Streptococcus pyogenes , IdeS.

177 occus aureus, Staphylococcus epidermidis and Streptococcus pyogenes in a soft-tissue wound biofilm mo

178 ld activate NF-kappaB in response to bRNA or Streptococcus pyogenes in an RNA-specific manner.

179 pha2 exhibited considerable activity against Streptococcus pyogenes, indicating a role of PSMs in the

180 rate that type I interferons produced during Streptococcus pyogenes infection are required to prevent

181 ated as an adjunctive treatment for clinical Streptococcus pyogenes infection however, the protein ta

182 , and laboratory testing for confirmation of Streptococcus pyogenes infection is required to prevent

183 ontrast to infection of superficial tissues, Streptococcus pyogenes infection of deeper tissue can be

184 t count are all hallmarks of severe invasive Streptococcus pyogenes infection, sepsis.

185 or optimal Th17 cell formation in mice after Streptococcus pyogenes infection.

186 ses that are associated with severe invasive Streptococcus pyogenes infections.

187 ded with an unexpected elevation in invasive Streptococcus pyogenes infections.

188 To obtain new information about Streptococcus pyogenes intrahost genetic variation durin

189 owed that the adhesive is capable of killing Streptococcus pyogenes introduced subcutaneously at the

190 While many virulence factors promoting Streptococcus pyogenes invasive disease have been descri

191 Streptococcus pyogenes is a human-restricted pathogen mo

192 Streptococcus pyogenes is a major bacterial pathogen and

193 Streptococcus pyogenes is a significant bacterial pathog

194 The RNA-guided Cas9 endonuclease from Streptococcus pyogenes is a single-turnover enzyme that

195 The ExPortal protein secretion organelle in Streptococcus pyogenes is an anionic phospholipid-contai

196 Streptococcus pyogenes is an exclusively human pathogen.

197 Streptococcus pyogenes is an important human pathogen th

198 Streptococcus pyogenes is an important human pathogen wi

199 Streptococcus pyogenes is an important pathogen that cau

200 epeats (CRISPR)-associated protein Cas9 from Streptococcus pyogenes is an RNA-guided DNA endonuclease

201 CRISPR-Cas9 from Streptococcus pyogenes is an RNA-guided DNA endonuclease

202 The cellular level of c-di-AMP in Streptococcus pyogenes is predicted to be controlled by

203 of maternal death in the United Kingdom, and Streptococcus pyogenes is the leading pathogen.

204 Type II-A SpCas9 protein from Streptococcus pyogenes is the most investigated and high

205 Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for whic

206 The group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive bacterial pat

207 The Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive human pathoge

208 Group A Streptococcus (GAS, Streptococcus pyogenes) is a human-restricted pathogen w

209 Two near-identical clinical Streptococcus pyogenes isolates of emm subtype emm43.4 w

210 LDH2 < E. faecalis LDH1 < L. lactis LDH1 </= Streptococcus pyogenes LDH.

211 h year, millions of people are infected with Streptococcus pyogenes, leading to an estimated 500,000

212 ombined with focused experimental testing in Streptococcus pyogenes, led to a better understanding of

213 f a catalytically inactive Cas9 (dCas9) from Streptococcus pyogenes loaded with single guide RNAs (sg

214 r Staphylococcus aureus (</=0.12 microg/mL), Streptococcus pyogenes (</=0.12 microg/mL), Streptococcu

215 nella enterica, Clostridioides difficile, or Streptococcus pyogenes, multiple highly conserved DNA MT

216 The Streptococcus pyogenes NAD(+) glycohydrolase (SPN) is se

217 ected mutagenesis of an endoglycosidase from Streptococcus pyogenes of serotype M49 (Endo-S2) and the

218 Streptococcus pyogenes, one of the most common human pat

219 Streptococcus pyogenes (or group A streptococcus [GAS])

220 Streptococcus pyogenes, or group A Streptococcus (GAS),

221 Streptococcus pyogenes, or group A Streptococcus (GAS),

222 re, and clears infection in a mouse model of Streptococcus pyogenes peritonitis.

223 ginosus group, Streptococcus pneumoniae, and Streptococcus pyogenes), positive percent agreement (PPA

224 The Gram-positive bacterial pathogen Streptococcus pyogenes produces a C3 family ADP-ribosylt

225 The human pathogen Streptococcus pyogenes produces pili that are essential

226 The pathogenic bacterium Group A Streptococcus pyogenes produces several extracellular DN

227 In the human pathogen Streptococcus pyogenes, production of secreted virulence

228 SpyCEP is a Streptococcus pyogenes protease that cleaves CXCL8/IL-8

229 Streptococcus pyogenes ranks among the main causes of mo

230 ar analysis conducted on streptolysin O from Streptococcus pyogenes revealed that this CDC also has g

231 Streptococcus pyogenes Rgg is a regulatory protein that

232 Streptococcus pyogenes Rgg is a transcriptional regulato

233 en was used to identify mutations in rgg2 of Streptococcus pyogenes (rgg2Sp ) that conferred pheromon

234 indigenous to the human mouth, as well as in Streptococcus pyogenes, S. agalactiae and S. suis.

235 The AF, but not the meconium SALSA, bound to Streptococcus pyogenes, S. agalactiae, S. gordonii, and

236 resent in pathogenic streptococci, including Streptococcus pyogenes, S. agalactiae, S. pneumoniae, an

237 The human pathogen Streptococcus pyogenes secretes a highly cytolytic toxin

238 Streptococcus pyogenes secretes many toxins that facilit

239 The globally prominent pathogen Streptococcus pyogenes secretes potent immunomodulatory

240 human pathogens Streptococcus pneumoniae and Streptococcus pyogenes, SEER identifies relevant previou

241 cluding that in group A Streptococcus (GAS) (Streptococcus pyogenes Ser/Thr kinase (SP-STK)), regulat

242 the eukaryote-type serine/threonine kinase (Streptococcus pyogenes serine/threonine kinase; SP-STK)

243 The first genome sequence of a group A Streptococcus pyogenes serotype M23 (emm23) strain (M23N

244 Here, we used Scl2 from Streptococcus pyogenes serotype M28 strain MGAS6274 as a

245 limitations, we have developed CRISPR-RGR, a Streptococcus pyogenes (Sp)Cas9-based gene editing syste

246 The CRISPR-associated endonuclease Cas9 from Streptococcus pyogenes (spCas9) along with a single guid

247 arget and off-target activities of Cas9 from Streptococcus pyogenes (SpCas9) and the SpCas9 variants

248 (CRISPR)-associated endonuclease (Cas)9 from Streptococcus pyogenes (SpCas9) can be used to edit sing

249 The RNA-guided CRISPR-Cas9 nuclease from Streptococcus pyogenes (SpCas9) has been widely repurpos

250 he exogenous protein Cas9 from the bacterium Streptococcus pyogenes (SpCas9) in plasma samples by mea

251 off-target cleavage compared with wild-type Streptococcus pyogenes (SpCas9) in vivo.

252 In vitro assays demonstrate that Cas9 from Streptococcus pyogenes (SpCas9) is more active in creati

253 (CRISPR)-associated endonuclease (Cas)9 from Streptococcus pyogenes (SpCas9) is used to deplete VEGFR

254 ver, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for b

255 c Cas9, the most widely used is derived from Streptococcus pyogenes (SpCas9), with a complementary sm

256 ivity of a transactivator based on Cas9 from Streptococcus pyogenes (SpCas9).

257 yC, a bacteriophage-encoded endolysin, lyses Streptococcus pyogenes (Spy) on contact.

258 acCas9 to its well-established ortholog from Streptococcus pyogenes (SpyCas9), and further engineer a

259 e measured affinities of Cas9 nucleases from Streptococcus pyogenes, Staphylococcus aureus, and Franc

260 for entry of other virulent pathogens (e.g., Streptococcus pyogenes, Staphylococcus aureus, and poten

261 e first complete, closed genome sequences of Streptococcus pyogenes strains NCTC 8198(T) and CCUG 420

262 identifying variation, we pooled DNA of 100 Streptococcus pyogenes strains of different emm types in

263 Recently, two related Streptococcus pyogenes strains with reduced susceptibili

264 Enterococcus faecalis, Enterococcus faecium, Streptococcus pyogenes, Streptococcus agalactiae, and St

265 eruginosa, S. aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus agalactiae, and vi

266 pathogens, including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Helico

267 against local and/or systemic infections by Streptococcus pyogenes, Streptococcus pneumoniae, Lister

268 rsA homologues encoded by Bacillus subtilis, Streptococcus pyogenes, Streptococcus pneumoniae, Strept

269 reproduce the canonical PAM preferences for Streptococcus pyogenes, Streptococcus thermophilus CRISP

270 ally increase mortality when associated with Streptococcus pyogenes superinfection.

271 The important human pathogen, Streptococcus pyogenes, synthesizes a key antigenic surf

272 ity factor (SOF), a virulence determinant of Streptococcus pyogenes that turns serum opaque.

273 /SpyCatcher), based on a protein domain from Streptococcus pyogenes, that locks itself together via s

274 toxin production and increased virulence in Streptococcus pyogenes The nature of the polymorphism is

275 type M1 and M3 strains of the human pathogen Streptococcus pyogenes (the group A Streptococcus [GAS])

276 As an exclusively human pathogen, Streptococcus pyogenes (the group A streptococcus [GAS])

277 l streptococci, including the human pathogen Streptococcus pyogenes(the group A Streptococcus[GAS]),

278 r model organisms, Staphylococcus aureus and Streptococcus pyogenes, the activity is dependent on pri

279 Herein we report that in the human pathogen Streptococcus pyogenes, the adaptive response to Mn limi

280 toxins produced by Staphylococcus aureus and Streptococcus pyogenes, the superantigens (SAgs) are the

281 In the human-pathogenic bacterium Streptococcus pyogenes, the tagatose bisphosphate aldola

282 protein against the Gram-positive bacterium Streptococcus pyogenes This protein is composed of two d

283 The ability of Streptococcus pyogenes to infect different niches within

284 ontaining Lancefield group A carbohydrate of Streptococcus pyogenes to study the effects of bacterial

285 ction of Staphylococcus aureus harboring the Streptococcus pyogenes type II-A CRISPR-Cas system.

286 To overcome these challenges, the pathogen Streptococcus pyogenes utilizes the protein Cpa, a pilus

287 n-mediated translocation (CMT), performed by Streptococcus pyogenes, utilizes the cholesterol-depende

288 The Cas9 protein from Streptococcus pyogenes was pre-complexed with a single g

289 ermore, utilization of supplied 5-CHO-THF by Streptococcus pyogenes was shown to require expression o

290 Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used

291 Studying the pilus tip adhesin Spy0125 of Streptococcus pyogenes, we developed a single molecule a

292 elical peptide epitope from the M protein of Streptococcus pyogenes, were designed by exchanging one

293 h a fluorescent antibody complex specific to Streptococcus pyogenes, were volumetrically normalized a

294 cterial enzyme IdeS (IgG-degrading enzyme of Streptococcus pyogenes), which selectively cleaves IgG a

295 betabetaalpha/metal-dependent nuclease from Streptococcus pyogenes, which is encoded by the SF370.1

296 It resembles the cel operon of Streptococcus pyogenes, which is implicated in the metab

297 e also analyzed promiscuity of epitopes from Streptococcus pyogenes, which is known to exhibit epitop

298 tting a pilin subunit from a human pathogen, Streptococcus pyogenes, which usually undergoes intramol

299 lence of many bacterial pathogens, including Streptococcus pyogenes, which utilizes the cholesterol-d

300 Invasive strains of Streptococcus pyogenes with significantly reduced suscep